Karyopharm Therapeutics Inc. announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer. Prior to joining Marengo, Dr. Su served as SVP, Global Head of Oncology Business Franchise, including US Head of the Oncology Business Unit, at Merck KGaA.

Prior to that, he served as Chief Medical Officer at EMD Serono and headed leadership functions at Sanofi's Oncology Division and GlaxoSmithKline. Before his industry career, Dr. Su served on the faculty of Duke University Medical School where he led early oncology clinical studies focusing on mRNA-based and cell-based immunotherapy and then at the University of Florida where he was the director of the Cell and Gene Therapy program. He received his Doctor of Medicine from Technical University of Dresden in Germany and his MBA from the University of Toronto in Canada.